Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | IDH1 R132X |
Gene Variant Detail | |
Relevant Treatment Approaches | IDH Inhibitor (Pan) IDH1 Inhibitor |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02977689 | Phase II | IDH305 | Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | Withdrawn | USA | 0 |
NCT02746081 | Phase I | BAY1436032 | Phase I Study of BAY1436032 in IDH1-mutant Advanced Solid Tumors | Active, not recruiting | USA | DEU | 2 |
NCT04493164 | Phase II | CPX-351 + Ivosidenib Ivosidenib | CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03564821 | Phase I | Ivosidenib | IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT03684811 | Phase Ib/II | Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib | A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | Completed | USA | GBR | FRA | ESP | AUS | 1 |
NCT04013880 | Phase Ib/II | Decitabine and Cedazuridine + Olutasidenib | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Withdrawn | 0 | |
NCT04603001 | Phase I | LY3410738 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | Active, not recruiting | USA | FRA | ESP | DEU | CAN | BEL | AUS | 5 |
NCT02381886 | Phase I | IDH305 | A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | Active, not recruiting | USA | NLD | ESP | DEU | CAN | BEL | AUS | 1 |
NCT04655391 | Phase I | Glasdegib Glasdegib + Ivosidenib Bosutinib + Glasdegib Gilteritinib + Glasdegib Decitabine + Glasdegib + Venetoclax Enasidenib + Glasdegib | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation | Withdrawn | USA | 0 |
NCT03471260 | Phase Ib/II | Azacitidine + Ivosidenib + Venetoclax Ivosidenib + Venetoclax | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | Recruiting | USA | 0 |
NCT03914742 | Phase Ib/II | Pamiparib + Temozolomide | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | Completed | USA | 0 |
NCT04521686 | Phase I | LY3410738 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | FRA | ESP | AUS | 5 |
NCT04250051 | Phase I | Cytarabine + Filgrastim + Fludarabine + Ivosidenib Ivosidenib | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03528642 | Phase I | Radiotherapy + Telaglenastat + Temozolomide | Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma | Active, not recruiting | USA | 0 |
NCT02719574 | Phase I | Cytarabine + Olutasidenib Olutasidenib Azacitidine + Olutasidenib | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT02074839 | Phase I | Ivosidenib | Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Recruiting | USA | FRA | 0 |
NCT03839771 | Phase III | Ivosidenib Enasidenib | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML) | Recruiting | NLD | FRA | ESP | DEU | BEL | AUT | AUS | 8 |